Urine levels of 5-aminoimidazole-4-carboxamide riboside (AICAR) in patients with type 2 diabetes
AIMS: 5-Aminoimidazole-4-carboxamide riboside (AICAR) is an endogenous activator of AMPK, a central regulator of energy homeostasis. Loss and/or reduction of AMPK signaling plays an important role in the development of insulin resistance in type 2 diabetes. The loss of AMPK in diabetes could be due...
Gespeichert in:
| Hauptverfasser: | , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2018
|
| In: |
Acta diabetologica
Year: 2018, Jahrgang: 55, Heft: 6, Pages: 585-592 |
| ISSN: | 1432-5233 |
| DOI: | 10.1007/s00592-018-1130-2 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s00592-018-1130-2
|
| Verfasserangaben: | Michael Mendler, Stefan Kopf, Jan B. Groener, Christin Riedinger, Thomas H. Fleming, Peter P. Nawroth, Jürgen G. Okun |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1693499207 | ||
| 003 | DE-627 | ||
| 005 | 20240405193208.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200330s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00592-018-1130-2 |2 doi | |
| 035 | |a (DE-627)1693499207 | ||
| 035 | |a (DE-599)KXP1693499207 | ||
| 035 | |a (OCoLC)1341311288 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Mendler, Michael |e VerfasserIn |0 (DE-588)1093415142 |0 (DE-627)853471533 |0 (DE-576)462676714 |4 aut | |
| 245 | 1 | 0 | |a Urine levels of 5-aminoimidazole-4-carboxamide riboside (AICAR) in patients with type 2 diabetes |c Michael Mendler, Stefan Kopf, Jan B. Groener, Christin Riedinger, Thomas H. Fleming, Peter P. Nawroth, Jürgen G. Okun |
| 264 | 1 | |c 2018 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 30.03.2020 | ||
| 520 | |a AIMS: 5-Aminoimidazole-4-carboxamide riboside (AICAR) is an endogenous activator of AMPK, a central regulator of energy homeostasis. Loss and/or reduction of AMPK signaling plays an important role in the development of insulin resistance in type 2 diabetes. The loss of AMPK in diabetes could be due to a loss of AICAR. The aim of this study was to characterize urine levels of AICAR in diabetes and determine whether an association exists with respect to late complications, e.g., retinopathy, nephropathy and neuropathy. - METHODS: Urine AICAR was measured by liquid chromatography tandem mass spectrometry in 223 patients consisting of 5 healthy controls, 63 patients with pre-diabetes, 29 patients with newly diagnosed type 2 diabetes and 126 patients with long-standing type 2 diabetes. For statistical analyses, nonparametric Kruskal-Wallis test, one-way ANOVA and multivariate regression analysis were performed to investigate the associations of urinary AICAR excretion within different groups and different clinical parameters. - RESULTS: The mean urine AICAR for all 223 patients was 694.7 ± 641.1 ng/ml. There was no significant difference in urine AICAR between the control and patients with diabetes (592.3 ± 345.1 vs. 697.1 ± 646.5 ng/ml). No association between any of the biochemical and/or clinical parameters measured and urine AICAR was found, with the exception of age of patient (R = - 0.34; p < 0.01) and estimated glomerular filtration rate (R = 0.19; p = 0.039). These results were confirmed additionally by linear regression analysis. - CONCLUSIONS: Clinical diabetes is not associated with a change in endogenous AICAR levels. Loss of AICAR may therefore not be a mechanism by which AMPK signaling is reduced in diabetes. | ||
| 650 | 4 | |a Adenylate Kinase | |
| 650 | 4 | |a Adult | |
| 650 | 4 | |a Aged | |
| 650 | 4 | |a AICAR | |
| 650 | 4 | |a Aminoimidazole Carboxamide | |
| 650 | 4 | |a AMPK | |
| 650 | 4 | |a Animals | |
| 650 | 4 | |a Case-Control Studies | |
| 650 | 4 | |a Cohort Studies | |
| 650 | 4 | |a Diabetes | |
| 650 | 4 | |a Diabetes Complications | |
| 650 | 4 | |a Diabetes Mellitus, Type 2 | |
| 650 | 4 | |a Female | |
| 650 | 4 | |a Humans | |
| 650 | 4 | |a Late diabetic complications | |
| 650 | 4 | |a Male | |
| 650 | 4 | |a Middle Aged | |
| 650 | 4 | |a Prediabetic State | |
| 650 | 4 | |a Ribonucleotides | |
| 650 | 4 | |a Risk Factors | |
| 650 | 4 | |a Risk Reduction Behavior | |
| 650 | 4 | |a Signal Transduction | |
| 650 | 4 | |a Urine analysis | |
| 700 | 1 | |a Kopf, Stefan |d 1978- |e VerfasserIn |0 (DE-588)1013047516 |0 (DE-627)663343453 |0 (DE-576)346399025 |4 aut | |
| 700 | 1 | |a Gröner, Jan |e VerfasserIn |0 (DE-588)1017332444 |0 (DE-627)676373771 |0 (DE-576)353490172 |4 aut | |
| 700 | 1 | |a Riedinger, Christin |d 1988- |e VerfasserIn |0 (DE-588)116290125X |0 (DE-627)1026994098 |0 (DE-576)507650522 |4 aut | |
| 700 | 1 | |a Fleming, Thomas |d 1982- |e VerfasserIn |0 (DE-588)1034445294 |0 (DE-627)745607365 |0 (DE-576)382066804 |4 aut | |
| 700 | 1 | |a Nawroth, Peter Paul |d 1954- |e VerfasserIn |0 (DE-588)1020504897 |0 (DE-627)69123941X |0 (DE-576)360517692 |4 aut | |
| 700 | 1 | |a Okun, Jürgen G. |d 1968- |e VerfasserIn |0 (DE-588)121578232 |0 (DE-627)705551415 |0 (DE-576)292781296 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Acta diabetologica |d Mailand : Springer, 1991 |g 55(2018), 6, Seite 585-592 |h Online-Ressource |w (DE-627)266886469 |w (DE-600)1468518-8 |w (DE-576)107470802 |x 1432-5233 |7 nnas |a Urine levels of 5-aminoimidazole-4-carboxamide riboside (AICAR) in patients with type 2 diabetes |
| 773 | 1 | 8 | |g volume:55 |g year:2018 |g number:6 |g pages:585-592 |g extent:8 |a Urine levels of 5-aminoimidazole-4-carboxamide riboside (AICAR) in patients with type 2 diabetes |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s00592-018-1130-2 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200330 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 121578232 |a Okun, Jürgen G. |m 121578232:Okun, Jürgen G. |d 910000 |d 910500 |e 910000PO121578232 |e 910500PO121578232 |k 0/910000/ |k 1/910000/910500/ |p 7 |y j | ||
| 998 | |g 1020504897 |a Nawroth, Peter Paul |m 1020504897:Nawroth, Peter Paul |d 910000 |d 910100 |e 910000PN1020504897 |e 910100PN1020504897 |k 0/910000/ |k 1/910000/910100/ |p 6 | ||
| 998 | |g 1034445294 |a Fleming, Thomas |m 1034445294:Fleming, Thomas |d 910000 |d 910100 |e 910000PF1034445294 |e 910100PF1034445294 |k 0/910000/ |k 1/910000/910100/ |p 5 | ||
| 998 | |g 116290125X |a Riedinger, Christin |m 116290125X:Riedinger, Christin |d 910000 |d 910100 |e 910000PR116290125X |e 910100PR116290125X |k 0/910000/ |k 1/910000/910100/ |p 4 | ||
| 998 | |g 1017332444 |a Gröner, Jan |m 1017332444:Gröner, Jan |d 910000 |d 910100 |e 910000PG1017332444 |e 910100PG1017332444 |k 0/910000/ |k 1/910000/910100/ |p 3 | ||
| 998 | |g 1013047516 |a Kopf, Stefan |m 1013047516:Kopf, Stefan |d 910000 |d 910100 |e 910000PK1013047516 |e 910100PK1013047516 |k 0/910000/ |k 1/910000/910100/ |p 2 | ||
| 998 | |g 1093415142 |a Mendler, Michael |m 1093415142:Mendler, Michael |d 910000 |d 910200 |e 910000PM1093415142 |e 910200PM1093415142 |k 0/910000/ |k 1/910000/910200/ |p 1 |x j | ||
| 999 | |a KXP-PPN1693499207 |e 3615728009 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Michael Mendler, Stefan Kopf, Jan B. Groener, Christin Riedinger, Thomas H. Fleming, Peter P. Nawroth, Jürgen G. Okun"]},"physDesc":[{"extent":"8 S."}],"recId":"1693499207","relHost":[{"language":["eng"],"part":{"volume":"55","extent":"8","issue":"6","text":"55(2018), 6, Seite 585-592","pages":"585-592","year":"2018"},"physDesc":[{"extent":"Online-Ressource"}],"recId":"266886469","id":{"eki":["266886469"],"zdb":["1468518-8"],"issn":["1432-5233"]},"title":[{"title_sort":"Acta diabetologica","title":"Acta diabetologica"}],"note":["Fortsetzung der Druck-Ausgabe","Gesehen am 03.06.24","Ungezählte Beil. ab Volume 39 (2002): Supplement"],"pubHistory":["Volume 28, issue 2 (June 1991)-"],"origin":[{"publisher":"Springer ; Springer","dateIssuedKey":"1991","dateIssuedDisp":"1991-","publisherPlace":"Mailand ; Berlin ; Heidelberg"}],"disp":"Urine levels of 5-aminoimidazole-4-carboxamide riboside (AICAR) in patients with type 2 diabetesActa diabetologica","type":{"bibl":"periodical","media":"Online-Ressource"}}],"id":{"doi":["10.1007/s00592-018-1130-2"],"eki":["1693499207"]},"note":["Gesehen am 30.03.2020"],"origin":[{"dateIssuedDisp":"2018","dateIssuedKey":"2018"}],"title":[{"title_sort":"Urine levels of 5-aminoimidazole-4-carboxamide riboside (AICAR) in patients with type 2 diabetes","title":"Urine levels of 5-aminoimidazole-4-carboxamide riboside (AICAR) in patients with type 2 diabetes"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"language":["eng"],"person":[{"role":"aut","given":"Michael","display":"Mendler, Michael","family":"Mendler"},{"family":"Kopf","display":"Kopf, Stefan","given":"Stefan","role":"aut"},{"display":"Gröner, Jan","family":"Gröner","role":"aut","given":"Jan"},{"display":"Riedinger, Christin","family":"Riedinger","given":"Christin","role":"aut"},{"given":"Thomas","role":"aut","family":"Fleming","display":"Fleming, Thomas"},{"family":"Nawroth","display":"Nawroth, Peter Paul","given":"Peter Paul","role":"aut"},{"role":"aut","given":"Jürgen G.","display":"Okun, Jürgen G.","family":"Okun"}]} | ||
| SRT | |a MENDLERMICURINELEVEL2018 | ||